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FIG. 2. hNIS mRNA expression in tall-cell papillary thyroid 
carcinoma. RT-PCR products were resolved on a 2% agarose gel 
and visualized by ethidium bromide staining. PCR substrates are: 
Lane 1, no cDNA (negative control); lane 2, normal thyroid (postive 
control); lanes 3-7, tall-cell papillary thyroid carcinomas (samples 
11~l5, Table l); and lane 8, GIBCO-BRL l kb-plus DNA ladder. 
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FIG. 4. Re-expression of hNIS mRNA in thyroid cell lines. 
Follicular adenoma cell line, KAKl (a). KAK-l cells were treated in 
triplicates, with 5-azacytidine as described. The RT-PCR products 
were resolved on a 2% agarose gel and visualized by ethidium 
bromide staining. lanel. no cDNA; lane 2 to 4. untreated; lanes 5 
to 7. 0.5 11M 5-azacytidine for 3 days (added each day); lanes 8 to 10. 
1.0 11M 5-azacytidine for 3 days (added each day); lane 11. GIBCO 
BRL 1 kb plus DNA ladder. Papillary carcinoma cell line, NPA'87 
(b). NPA'87 cells were treated in triplicates, with sodium butyrate 
or 5-azacytidine as described. The RT-PCR products were resolved 
on a 2% agarose gel and visualized by ethidium bromide staining. 
lanel. GIBCO-BRL 1 kb plus DNA ladder; lane 2. normal human 
thyroid; lane 3 to 5. untreated; lanes 6 to 8. 1.0 mM sodium 
butyrate for 3 days; lanes 9 to 11. 1.0 11M 5-azacytidine for 3 days 
(added each day). 
U.S. Patent Apr. 18, 2006 Sheet 5 0f 7 US 7,029,879 B1 
I net uptake I MTI' 
a) nhnw 
10000‘ 
8000' 
6000‘ 
4000‘ 
2000 
9553 uuEo. oEowam
control 0.5pM Aza-C 1.0|.|M Aza-C 
Restoration of iodide uptake in KAK-l Cells 
U.S. Patent Apr. 18, 2006 Sheet 6 0f 7 US 7,029,879 B1 
F75. § 
60000 
I net uptake! MTT 
50000 - (n = 4) 
0: 
€ 
5 40000 — 
D 
g 
E 30000 - 
.2 
.2 
\l- _ 
.6 20000 
m 
o. 
(D 
10000 - 
o - 
control 1.0mM NaB 1.0|.|M Aza-C 
Restoration of iodide uptake in NPA '87 Cells 
U.S. Patent Apr. 18, 2006 Sheet 7 of 7 US 7,029,879 B1 
6a 6b 
bp bp 
400 400 
200 
20° 1 a 5 7 9 1113151719 21 13 5 7 9111315171921 
6c 6d 
FIG. 6. Methylation analysis of hNIS gene regions in cell 
lines re-expressing hNIS mRNA. Products of methylation 
speci?c-PCB analysis of sodium bisul?te modi?ed genomic DNA, 
from thyroid cell lines, using two methylation-speci?c primer pairs 
(MET for regions L and C) and two corresponding non—methylated 
speci?c primer pair (UNMET for regions L and C) were 
elecrophoresed on an agarose gel in adjacent lanes. In all gels, 
lanes 1 and 22: GIBCO-BRL 1 kb plus DNA ladder; lanes 2 through 
7: triplicate pairs of cell lines under basal conditions; lanes 8 
through 19: triplicate pairs of cell lines in two different treatment 
conditions; lanes 20 and 21: negative controls without template 
DNA (all even numbered lanes contain the respective UNMET 
products and odd numbered lanes contain the correponding MET 
products). Cell line KAK-l studied with primer pairs speci?c for 
region L (a). Treatment conditions in lanes 8-13 and lanes 14-19 
include 5-azacytidine at 0.5 pM and 1.0 pM, respectively. Cell line 
KAK-l studied with primer pairs speci?c for region C (b), with 
conditions identical to (8.7. Cell line NPA'87 studied with primer 
pairs speci?c for region L (c). Treatment conditions in lanes 8-13 
and lanes 14-19 include sodium butyrate at 1.0 mM and 5 
azacytidine at 1.0 11M, respectively. Cell line NPA'87 studied with 
primer pairs speci?c for region C (d), with conditions identical to (c). 
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IODINE UPTAKE RESTORATION IN 
THYROID CANCER 
CONTINUING DATA 
This application claims the bene?t of priority to US. 
Provisional Application No. 60/140,976, ?led Jun. 29, 1999, 
the contents of Which are incorporated herein by reference in 
their entirety. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to a method for expressing 
a gene product that could not be expressed because of 
blockage occurring in a regulatory region of the gene. The 
present invention also relates to a method of restoring iodide 
transport in cells defective in iodide transport. The present 
invention is also directed to a method of treating tumors by 
expressing tumor speci?c therapeutic response element in a 
cancerous cell in Which the response element Was blocked 
from expression. 
2. Brief Description of the Related Art 
The initial step in the synthesis of thyroid hormone is the 
active transport of iodide, mediated by the sodium-iodide 
sympor‘ter (NIS) located in the basolateral membrane of 
thyroid follicular cells (1). This iodide-concentrating ability 
of thyroid follicular cells is exploited for the treatment of 
differentiated thyroid epithelial carcinomas, using therapeu 
tic dosages of I-131. Loss of iodide concentrating ability, in 
the face of distantly metastatic disease, results in signi?cant 
morbidity and mortality for around 10% of patients With 
differentiated thyroid cancers (2). In addition, anaplastic 
thyroid cancers, Which are unable to take up radioactive 
iodide and do not respond to systemic chemotherapies, are 
invariably fatal. 
The complementary DNA sequence for human NIS 
(hNIS), as Well as the exon-intron organization, have been 
revealed by Smanik et al (3,4). The cloning and character 
iZation of a 1.3 kb region of the upstream regulatory region 
Was reported and a minimal essential hNIS promoter that 
shoWs tissue-speci?c expression in a human thyroid cell line 
Was de?ned (5). Other investigators have further evaluated 
hNIS promoter constructs (6,7). It is possible that alterations 
in hNIS expression, responsible for loss of iodide-concen 
trating ability in human thyroid cancer metastases, may 
correspond to changes in hNIS promoter activity. This may 
be similar to the loss of E-cadherin expression demonstrated 
in human thyroid cancer cell lines, correlating to methyla 
tion of CpG islands in the E-cadherin promoter (8). Since the 
hNIS promoter has CpG-rich regions, as Well as additional 
CpG islands doWnstream from the transcription start site, 
DNA methylation may be responsible for alterations in hNIS 
expression. The DNA sequence corresponding to the mini 
mal essential promoter of the gene encoding hNIS has been 
reported (49). The contents of this reference are incorporated 
herein by reference in their entirety. 
Nearly half of all human genes have CpG islands asso 
ciated With transcriptional start sites. Unmethylated CpG 
islands are seen in highly transcribed genes, While heavily 
methylated CpG islands inhibit transcription (9). Although 
overall DNA methylation is often decreased in cancers, CpG 
islands in critical gene promoter regions can become hyper 
methylated, resulting in loss of gene expression (10). Such 
methylation may be effective in silencing gene expression 
despite variable degrees of CpG site methylation from 20 to 
100% (11). Laboratory and clinical studies have suggested 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
2 
that chemical agents may demethylate these regions and 
restore gene expression. Examples include use of: 5-aZacy 
tidine to restore expression of O6-methylguanine-DNA 
methyltransferase in human cervical, brain, and colon car 
cinomas (12,13); phenylacetate to induce fetal hemoglobin 
expression in human leukemic cells (14); and sodium 
butyrate to induce prolactin receptor expression in human 
breast cancer cells (15). 
The present invention is directed to a method of control 
ling transcriptional expression of a gene by a multi-faceted 
epigenetic approach. That is, the gene of interest is tran 
scriptionally regulated by modifying the chromosome struc 
ture Without mutating the bases in the DNA. Several 
examples of epigenetic modi?cations of the chromosome are 
included in the invention, Without limitation. Administration 
of butyrate, for example, results in the acetylation of his 
tones, thereby resulting in a more “open” chromatin struc 
ture facilitating transcriptional activation (50452). Phospho 
rylation of the nucleosome similarly alters the chemical and 
physical properties of the nucleosome, thereby alloWing 
greater or lesser access to a speci?c trans- acting factor that 
may bind to a speci?c region on the DNA (55456). Also, 
administration of certain critical amounts of endogenous or 
exogenous DNA binding agents, such as polyamines, cause 
the level of transcriptional activity of a gene to alter in part 
because of the change in the chemical and physical proper 
ties of the modi?ed nucleosome (53454). Thus, it can be 
seen that the methods of demethylating or inhibiting methy 
lation of DNA, as exempli?ed herein, serves as merely an 
illustration of transcriptional regulation engendered by epi 
genetic modi?cation of chromosomes. 
In the present invention methylation of the characterized 
hNIS promoter, and potentially regulatory doWnstream 
regions, and their correlation With loss of hNIS mRNA 
expression, as Well as clinical loss of iodide uptake, in 
samples of thyroid tumor tissues Were tested. In addition, 
using human thyroid carcinoma cell lines and putative 
demethylation agents, the reversibility of loss of hNIS 
mRNA expression and functional activity, measured as 
iodide uptake Were evaluated. 
SUMMARY OF THE INVENTION 
The present invention is also directed to a method of 
expressing a tumor speci?c therapeutic response element in 
a cancerous cell in Which the response element Was blocked 
from expression, comprising the step of administering an 
unblocking agent to the cancerous cell harboring a gene 
encoding the response element, thereby resulting in the 
expression of the response element. 
The gene of interest may be a gene that is endogenous to 
the cancerous cell, or may be exogenous to the cancer cell, 
as introduced to the cancer cell by transfection technique, for 
example. Preferably, the gene encodes a sodium-iodide 
sympor‘ter (N IS). More preferably, the gene may encode a 
human sodium-iodide sympor‘ter (hNIS). 
The cell may be any cancerous cell, but is preferably a 
thyroid-derived cell. More preferably, the cells are dedilfer 
entiated. In the present invention, a tumor speci?c therapeu 
tic response element that Was turned off during dedilferen 
tiation is caused to be re-expressed. The tumor speci?c 
therapeutic response element may be a tumor speci?c anti 
gen that may serve as a target for a therapeutic antibody, or 
it may be an iodine transporter such that radioactive iodine 
may be captured and retained in the cancerous cells. The 
tumor speci?c therapeutic response element may be any 
factor that is speci?cally expressed by cancerous cells and 
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may serve as a speci?c target for therapy, and therefore is not 
limited to the particular forms exempli?ed herein. 
The blockage of transcriptional activation of the tumor 
speci?c therapeutic response element can occur in a variety 
of Ways. One of these Ways is through DNA methylation of 
certain sequence in or near the regulatory region, the pro 
moter, or the coding sequence. Preferably, CpG islands that 
may be present are the sites of methylation. The present 
invention exempli?es demethylation as a method of activat 
ing transcription of a gene. But the invention is not limited 
to the demethylation method alone. Other methods include 
inhibiting the methylation of DNA sequences. The demethy 
lating agent may be any chemical or enZymatic compound or 
mechanism that demethylates nucleic acids, and is prefer 
ably, but not limited to, dimethylsulfoxide, sodium butyrate, 
phenylacetate, or 5-aZacytidine. The demethylating agent 
may also include a compound that inhibits DNA-methyl 
transferase activity. Furthermore, the unblocking agent may 
include a compound that directly inhibits methylation of a 
DNA sequence, or indirectly inhibits methylation by an 
agent that depletes polyamines. Preferably, the agent inhibits 
the synthesis of polyamines include, but not limited to, 
di?uoromethylomithine(DFMO) and adenosyl-1,8-diamino 
3-thio-octane. 
The present invention is also directed to a method of 
restoring iodide transport to dedifferentiated thyroid cancer 
cells comprising the step of administering a demethylating 
agent in an amount effective to transcriptionally activate a 
tumor speci?c therapeutic response element in a cell that is 
defective in iodide transport. Preferably, the tumor speci?c 
therapeutic response element is the sodium iodide sym 
porter. 
Another object of the invention is to provide a demethy 
lating or methylation inhibiting agent that can transcription 
ally activate or unblock the expression of the trans- acting 
factor speci?c for the regulation of the speci?c therapeutic 
response element. This further extends to the expression of 
other trans- acting factors in the regulatory cascade. 
The present invention is also directed to a method of 
treating a tumor by expressing a tumor speci?c therapeutic 
response element in a cancerous cell in Which the response 
element Was blocked from expression, Which comprises the 
steps of: 
a) administering an unblocking agent to the cancerous cell 
harboring a gene encoding the response element, 
thereby resulting in the expression of the response 
element; and 
b) administering a therapeutic substance to target said 
tumor speci?c therapeutic response element. 
These and other objects of the invention Will be more fully 
understood from the folloWing description of the invention, 
the referenced draWings attached hereto and the claims 
appended hereto. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The present invention Will become more fully understood 
from the detailed description given hereinbeloW, and the 
accompanying draWings Which are given by Way of illus 
tration only, and thus are not limitative of the present 
invention, and Wherein; 
FIG. 1 shoWs CpG dinucleotide frequency in the hNIS 
promoter region. The DNA sequence of the hNIS promoter 
and its contiguous transcribed region (up to the ?rst intron), 
Was assessed by computer analysis. Nucleotide positions are 
in reference to the adenosine residue of the ATG translation 
start site. The bold arroW indicates the position of a ‘TATA’ 
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box-like element. The shaded box (P) denotes the region of 
the hNIS promoter chosen for methylation analysis. The 
open box (L) and the solid box (C) denote the leader and 
coding regions, respectively, of the ?rst exon Which Were 
analyZed for methylation status. 
FIG. 2 shoWs hNIS mRNA expression in tall-cell papil 
lary thyroid carcinoma. RT-PCR products Were resolved on 
a 2% agarose gel and visualiZed by ethidium bromide 
staining. PCR substrates are: Lane 1, no cDNA (negative 
control); lane 2, normal thyroid (positive control); lanes 3*7, 
tall-cell papillary thyroid carcinomas (samples 11*15, Table 
1); and lane 8, GIBCO-BRL 1 kb-plus DNA ladder. 
FIG. 3 shoWs methylation analysis of the hNIS promoter 
in proximity to TATA box (Region P). Products of methy 
lation speci?c-PCR analysis of sodium bisul?te modi?ed 
genomic DNA from thyroid tumors using a methylation 
speci?c primer pair (MET) and non-methylation-speci?c 
primer pair (UNMET) Were electrophoresed on an agarose 
gel in adjacent lanes. Lanes 1 and 22: GIBCO-BRL 1 kb plus 
DNA ladder; lanes 2 through 21 (even numbered lanes 
contain the 151 bp UNMET product and odd numbered 
lanes contain the 143 bp MET product). Lane pairs starting 
With 2 to 12 represent the reaction pairs of tall cell papillary 
cancer samples 11 through 16, respectively (Table 1). Lane 
pairs starting With 14 through 20 represent the reaction pairs 
for anaplastic carcinoma (Table 1, Sample 22), negative 
control (no template DNA), normal thyroid and pooled 
human leukocyte DNA, respectively. 
FIGS. 4a, b. shoWs re-expression of hNIS mRNA in 
thyroid cell lines. Follicular adenoma cell line, KAKI (a). 
KAK-l cells Were treated in triplicates, With 5-aZacytidine 
as described. The RT-PCR products Were resolved on a 2% 
agarose gel and visualiZed by ethidium bromide staining. 
lane 1. no cDNA; lane 2 to 4. untreated; lanes 5 to 7. 0.5 uM 
5-aZacytidine for 3 days (added each day); lanes 8 to 10. 1.0 
uM 5-aZacytidine for 3 days (added each day); lane 11. 
GIBCO-BRL 1 kb plus DNA ladder. Papillary carcinoma 
cell line, NPA’87 (b). NPA’87 cells Were treated in tripli 
cates, With sodium butyrate or 5-aZacytidine as described. 
The RT-PCR products Were resolved on a 2% agarose gel 
and visualiZed by ethidium bromide staining. lane 1. 
GIBCO-BRL 1 kb plus DNA ladder; lane 2. normal human 
thyroid; lane 3 to 5. untreated; lanes 6 to 8. 1.0 mM sodium 
butyrate for 3 days; lanes 9 to 11. 1.0 uM 5-aZacytidine for 
3 days (added each day). 
FIGSS. 5a, b. shoWs restoration of iodide uptake in 
neoplastic thyroid cell lines. The uptake values are normal 
iZed for cell viability, as determined by the MTT assay in a 
parallel set of plates. Follicular adenoma cell line, KAK-l 
(a). The KAK-l cells Were treated With 5-aZacytidine and 
the iodide uptake Was measured, in quadruplicates, as 
described. Papillary carcinoma cell line, NPA’87 (b). The 
NPA’87 cells Were treated With sodium butyrate or 5-aZa 
cytidine and the iodide uptake Was measured, in quadrupli 
cates, as described. 
FIGS. 6 aid. shoWs methylation analysis of hNIS gene 
regions in cell lines re-expressing hNIS mRNA. Products of 
methylation speci?c-PCR analysis of sodium bisul?te modi 
?ed genomic DNA, from thyroid cell lines, using tWo 
methylation-speci?c primer pairs (MET for regions L and C) 
and tWo corresponding non-methylated-speci?c primer pair 
(UNMET for regions L and C) Were electrophoresed on an 
agarose gel in adjacent lanes. In all gels, lanes 1 and 22: 
GIBCO-BRL 1 kb plus DNA ladder; lanes 2 through 7: 
triplicate pairs of cell lines under basal conditions; lanes 8 
through 19: triplicate pairs of cell lines in tWo different 
treatment conditions; lanes 20 and 21: negative controls 
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Without template DNA (all even numbered lanes contain the 
respective UNMET products and odd numbered lanes con 
tain the corresponding MET products). Cell line KAK-l 
studied With primer pairs speci?c for region L (a). Treatment 
conditions in lanes 8413 and lanes 14419 include 5-aZacy 
tidineat 0.5 HM and 1.0 uM, respectively. Cell line KAK-l 
studied With primer pairs speci?c for region C (b), With 
conditions identical to (a). Cell line NPA’87 studied With 
primer pairs speci?c for region L (c). Treatment conditions 
in lanes 8413 and lanes 14419 include sodium butyrate at 1.0 
mM and 5-aZacytidine at 1.0 uM, respectively. Cell line 
NPA’87 studied With primer pairs speci?c for region C (d), 
With conditions identical to (c). 
DETAILED DESCRIPTION OF THE 
INVENTION 
As used herein, “block”, “blocking” or “blockage” means 
the inhibition or transcription of a gene of interest. The 
inhibition includes, but is not limited to, methylation of 
certain regions on the gene of interest. The region methy 
lated on the gene includes the promoter, other regulatory 
regions, and the coding sequence. It is to be understood that 
the term “blockage” encompasses inhibition of a gene’s 
expression by any means. This includes the context of a gene 
of interest not being expressed because its speci?c trans 
acting factor is either not made or is non-functional. 
As used herein, “unblock(s)” means the transcriptional 
activation or expression of a gene Which Was previously 
inhibited from being expressed. The activation may be 
caused by, but is not limited to, demethylation or inhibition 
of methylation of the relevant regions on the gene. 
As used herein, “regulatory sequence” or “regulatory 
region” refers to a non-coding portion of a gene Which 
regulates activation or expression of the gene product. The 
regulatory sequence may include, but is not limited to, the 
promoter, as Well as certain DNA sequences upstream of the 
promoter that are cis- acting regions for binding by trans 
acting factors. Regulatory sequences may exist near or at the 
doWnstream end of the gene, or even in the middle of the 
gene in the form of introns. 
Treatment of metastatic thyroid carcinoma requires effec 
tive systemic agents. Due to the absence of applicable 
chemotherapeutics, radioiodine therapy is the only ef?ca 
cious modality. The failure to respond to radioiodine por 
tends grave consequences and is an appropriate target for 
correction. Loss of hNIS gene expression appeared a likely 
cause for loss of iodide concentrating ability; hoWever the 
inventors have demonstrated that some thyroid cancers 
maintain expression of hNIS mRNA despite loss of function, 
suggesting diverse pathophysiology. This Was of particular 
surprise for anaplastic carcinomas since these tumors do not 
have clinical iodide uptake (5). In those tumors in Which loss 
of hNIS mRNA Was observed, potential mechanisms Were 
explored, focusing on reversible etiologies. 
Some investigators have attempted to restore iodide 
uptake using retinoids. A nominal increase in iodide uptake 
activity Was reported in a thyroid follicular carcinoma cell 
line UCLA RO 82 W-l (WRO82), treated With l3cis 
retinoic acid (cRA) (27). Direct evidence of the effects of 
cRA on re-establishing iodide uptake in dedilferentiated 
follicular and papillary thyroid cancers Was ?rst reported by 
Simon et al (28). The latest details of their study revealed 
that only 14 patients (out of 20 study patients) did not 
concentrate any radioiodine in metastatic tumors at baseline, 
With only one such patient re-establishing distinct iodide 
uptake after cRA treatment (an additional three patients 
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gained “Weak” uptake) (29). A case report suggests a posi 
tive response to similar treatment in a single patient (30). 
Alternatively, a minimal enhancement of iodide uptake With 
gamma interferon Was suggested in several human thyroid 
cancer cell lines in vitro (31). The mechanism for effects on 
iodide transport is unknoWn for both of those agents 
although they suggest that loss of hNIS activity may be a 
reversible phenomenon. 
In vieW of the multiplicity of mechanisms causing loss of 
iodide transport, the inventors further evaluated the sub set of 
tumors With apparent hNIS transcriptional failure and the 
relationship to CpG island methylation in the region of the 
hNIS promoter. This Was of particular importance in tall-cell 
variant papillary thyroid cancers since nearly half of such 
patients lose clinical iodide transport (32,33), and the inven 
tors shoW this to be a consequence of hNIS transcriptional 
failure. The ability of 5-aZacytidine to induce hNIS mRNA, 
as Well as iodide uptake, in thyroid carcinoma cell lines 
devoid of basal hNIS mRNA expression, further implicated 
methylation as a likely mechanism. In these cell lines, 
reversal of basal methylation of the L and C regions 
appeared associated With de novo induction of hNIS expres 
sion. On the other hand, lack of expression of hNIS mRNA 
in tall-cell variant papillary carcinoma tumors Was not able 
to be assuredly explained by such methylation patterns. Part 
of the reason may relate to heterogeneity of cell methylation 
patterns betWeen cells in the same culture. This may relate 
to the heterogeneity of hNIS protein expression demon 
strated in normal and malignant thyroid tissues (34,35). A 
similar mechanism has been invoked for expression of 
p16 a in thyroid carcinoma cell lines and tumors (36). 
Likewise, tumor tissue samples are inherently heteroge 
neous as mixtures of tumor cells, ?broblasts, endothelial 
cells, smooth muscle cells, and in?ltrating host immune 
cells. It is also possible that the speci?c sites of methylation 
responsible for loss of hNIS transcription, in or near the 
hNIS gene, may be different from the particular sites ana 
lyZed in this study. 
Alternative explanations for loss of hNIS mRNA expres 
sion may relate to methylation of thyroid-speci?c transcrip 
tion factor genes causing loss of transcription factor expres 
sion With indirect loss of hNIS mRNA expression. This Was 
indicated by the KAT-5 and KAT-l0 responses to 5-aZacy 
tidine treatment With acquisition of parallel TTF-l and hNIS 
mRNA expression. Failure to express suf?cient TTF-l and 
PAX-8 can result in decreased activity of the thyroglobulin 
gene promoter in human thyroid carcinoma cells (37), a 
likely feature of the hNIS gene. Since additional, possibly 
complex, processes may affect post-transcriptional hNIS 
function, there are multiple opportunities for gene methyla 
tion to reduce iodide transport. 
There are several examples of DNA methylation altering 
expression of thyroid-speci?c genes. In transgenic mice 
carrying the chloramphenicol acetyltransferase (CAT) gene 
under control of a bovine thyroglobulin promoter, CAT 
expression Was limited to the thyroid glands and Was related 
to thyroid-speci?c demethylation of the bovine thyroglobu 
lin promoter (41). In another example, the transformed rat 
thyroid cell line, FRT, is unable to express its native TSH 
receptor gene, consequent to methylation of its promoter 
(42). Avvedimento et al (43,44) have shoWn that transfor 
mation of a rat thyroid cell line, Which activated the RAS 
oncogene, resulted in loss of activity of the thyroglobulin 
gene promoter, as Well as loss of expression of a thyroid 
speci?c trans-acting factor (presumably TTF-l). Treatment 
With 5-aZacytidine restored both TTF-l expression and 
thyroglobulin promoter activity. Such cases provide evi 
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dence that thyroidal tissues use methylation as a regulatory 
mechanism for gene expression, particularly in transformed 
phenotypes. 
The potential to restore iodide transport in dedilferenti 
ated thyroid carcinomas With demethylation agents suggests 
clinical application. The degree of hNIS expression needed 
to deliver tumoricidal radioiodide is not clear. Normal 
thyroid tissue, stimulated by TSH, concentrates radioiodide 
at 1% of the administered dose per gram of tissue. Dilfer 
entiated thyroid cancer metastases typically concentrate 
radioiodide at 0.06 to 0.3% of the administered radioiodide 
dose per gram of tumor (45). Calculations of the degree of 
radioiodide uptake and biologic residence time needed for 
sufficient therapy of thyroid cancer suggest that (employing 
an effective half-life of at least 4.5 days) tumor destruction 
can be achieved despite an uptake of only 0.1%, using 
administered activities of 300 mCi (46). Use of radioiodide 
dosimetry analysis, to verify upper safety margins of admin 
istered doses, may permit therapy doses exceeding 600 mCi 
(47) so that tumors With less than 0.05% uptake may respond 
to treatment. For this reason, restoration of hNIS activity 
sufficient to treat thyroid cancer does not require hNIS 
expression to the levels seen in normal human thyroid 
follicular cells. 
Effective radioiodide therapy requires more than a func 
tional hNIS gene. There should be sufficient expression of 
TSH receptors and doWnstream signal transduction machin 
ery to amplify hNIS expression When TSH levels rise. In 
addition, failure to organify radioiodide compromises I-131 
residence time in thyroid carcinoma cells, permitting radio 
iodide ef?ux and insu?icient radiation delivery. This Was 
seen by Shimura et al (48) When they transfected trans 
formed rat thyroid cells, lacking endogenous NIS expres 
sion, With rat NIS cDNA and restored radioiodide uptake. 
The Shimura et al. reference is incorporated herein by 
reference in its entirety. Despite high levels of I-131 uptake 
in xenografts of these cells, they Were unable to obtain 
tumoricidal effects due to rapid radioiodide ef?ux from lack 
of effective organi?cation. Demethylation therapy may be 
able to restore additional critical functions, such as organi 
?cation, doWnstream from iodide transport. 
The folloWing examples are offered by Way of illustration 
of the present invention, and not by Way of limitation. 
EXAMPLES 
Example 1 
Materials and Methods 
Cell Lines and Human Tissues 
Human thyroid cell lines used Were: MRO87 and WRO82 
(both follicular carcinomas), NPA’87 (papillary carcinoma), 
KAT-5 and KAT-10 (both papillary carcinomas (16)), 
KAK-l (benign follicular adenoma (17)), and KAT-7 (be 
nign follicular hyperplasia). Cultures Were previously 
treated With medium containing D-valine (18) and cis-4 
hydroxy-L-proline (19) to ensure the absence of ?broblasts. 
Human thyroid tissues Were obtained from fresh surgical 
samples (approved by University of Kentucky Institutional 
RevieW Board). Some tumor samples Were supplied by the 
Cooperative Human Tissue NetWork (Philadelphia, Pa.) and 
some Were obtained from surgical samples at the Clinical 
Center, National Institutes of Health, Bethesda, Md. (under 
approved protocol). 
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Cell Culture 
Cell lines, for evaluation of iodide-uptake and hNIS 
expression, Were groWn in phenol-red-free RPMI 1640 With 
5% fetal bovine serum (FBS), 100 nM sodium selenite and 
0.1 nM bovine TSH (basal medium) (20). They Were plated 
at a density of 345x104 cells/9.4 cm2, in triplicate in basal 
medium, and groWn for 243 days at 37° C. in 5% CO2. They 
Were treated With dimethylsulfoxide (DMSO, 25 uM daily 
for 3 days), sodium butyrate (0.5 or 1.0 mM), phenylacetate 
(pH 7.0, 5 or 10 mM) or 5-aZacytidine (0.5 or 1.0 uM, in 25 
uM DMSO, daily for 3 days) until control cells Were 80% 
con?uent (344 days), then changed to fresh basal medium 
and groWn for an additional 24 hrs. 
Analysis of CpG Content in the hNIS Gene Sequence 
The hNIS gene sequence of the 5' ?anking region (5) and 
the contiguous transcribed region extending up to the ?rst 
intron (3,4), Was analyZed using WINDOW and STATPLOT 
computer programs (Genetics Computer Group, Madison, 
Wis.) to denote CpG dinucleotide frequencies. 
Nucleic Acid Isolation and Ampli?cation 
Total RNA and genomic DNA from: normal human 
thyroid, thyroid tumors, and cell lines (treated With agents 
described above), Were isolated by the acid-guanidinium 
phenol-chloroform method (21). All surgical samples Were 
snap-froZen and stored at —80° C. until processed by homog 
eniZation in TriZol reagent (Life Technologies, Gaithersburg, 
Md.) While still froZen. Complementary DNA (cDNA) Was 
synthesiZed from 1.0 ug of total RNA using MMLV reverse 
transcriptase (RT) With random-hexamer primers (Clontech, 
Palo Alto, Calif.). Each 50 pL polymerase chain reaction 
(PCR) vessel contained: 60 mM Tris HCl, pH 9.0, 15 mM 
ammonium sulfate, 3.5 mM MgCl2 (1.5 mM for hTTF-l), 
250 uM dNTPs (Boehringer-Mannheim, Indianapolis, Ind.), 
0.2 uM each primer pair, 1 U AmpliTaq DNA polymerase 
(Perkin-Elmer, NorWalk, Conn.), 0.2 ug TaqStart Antibody 
(Clontech) and 3% cDNA. [3-actin ampli?cation (primers, 
Stratagene, La Jolla, Calif.) con?rmed cDNA integrity, 
purity, and template equivalence for semiquanti?cation. 
PCR primers (upstream 5' to 3'/doWnstream 5' to 3', in all 
cases) used for ampli?cation Were, for hNIS (5), CTGC 
CCCAGACCAGTACAT GCC (SEQ ID NO. 1)/TGACG 
GTGAAGGAGCCCTGAAG (SEQ ID NO. 2) (to amplify a 
coding region spanning four introns (4) yielding a 303 bp 
product from cDNA) and for Pax-8, AAGTCCAGCAT 
TGCGGCACA (SEQ ID NO. 3)/GAGGGAAGTGCT 
TATGGTCC (SEQ ID NO. 4)((22) to amplify a 329 bp 
product). Ampli?cation conditions for hNIS and Pax-8 Were: 
denaturation (95° C.><5 min); 40 cycles of 20 sec at 95° C. 
and 60 sec at 68° C.; folloWed by extension at 72° C. for 3 
min. The hTTF-l product Was ampli?ed With intron span 
ning primers, GCCGTACCAGGACACCATGAG (SEQ ID 
NO. 5)/CAGGTACTTCTGTTGCTTGAAG (SEQ ID NO. 
6), Which amplify a 263 bp fragment. The conditions Were: 
95° C. for 5 min; 45 cycles of 95° C. for 20 sec, 60° C. for 
60 sec, and 72° C. for 30 sec; folloWed by extension at 72° 
C. for 3 min. The RT-PCR products Were resolved on 2% 
agarose gels and visualiZed by ethidium bromide staining. 
Methylation-Speci?c Polymerase Chain Reaction (MS 
PCR) Analysis 
This method utiliZes PCR primer pairs to distinguish 
methylated from unmethylated DNA in bisul?te-modi?ed 
target DNA, in Which bisul?te converts unmethylated 
cytosines to uracil (23,24). Genomic DNAs, from normal 
and tumoral human thyroid tissues and cell lines, Were 
isolated by standard techniques (21) and 1.0 ug aliquots 
Were denatured by NaOH (10 min at 37° C.), then treated 
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With 10 mM hydroquinone and 3.0 M sodium hisul?te (pH 
5.0 under mineral oil for 16 hrs at 50° C.). Modi?ed DNA 
Was puri?ed on a resin column (Qiagen) and further treated 
With 0.3 N NaOH for 5 min prior to ethanol precipitation. 
The PCR mixture contained 16.6 mM ammonium sulfate, 67 
mM Tris-HCl (pH 8.8), 6.7 mM MgCl2, 10 mM [3-mercap 
toethanol, 1.25 mM dNTPs, 0.2 ML TaqStart antibody, 1 U 
AmpliTaq DNA polymerase, 10 pmoles each of sense and 
antisense methylation-speci?c primers, and 50 mg of hisul 
phite-modi?ed DNA target. Primers used for analysis of the 
hNIS promoter CpG island methylation Were selected for 
cytosine-rich regions, containing CpG dinucleotides near the 
3' end of the primers, hNIS-MET-P (sense, 5' to 3', TTAG 
GTTTGGAGGCGGA GTCGC (SEQ ID NO. 7) and anti 
sense, 5' to 3', ACCGACTATCTATCCCT CTC 
CCTAAACG) (SEQ ID NO. 8) for a 143 hp product from 
methylated DNA and hNIS-UNMET-P (sense, 5' to 3', 
TTGTTTTTAGGTTTGGAGGTG GAGTTGT (SEQ ID 
NO. 9) and antisense, 5' to 3', CAACCAACTATCTATC 
CCTCTC CCTAAACA) (SEQ ID NO. 10) for a 151 hp 
product from unmethylated genomic DNA. Additional sets 
of primers Were similarly designed to analyZe further doWn 
stream elements. They Were: hNIS-MET-L (sense, ATA 
GATAGATAGTAGGGGCGGAC (SEQ ID NO. 11) and 
antisense, GACCT CCATAAAAACGAATACG) (SEQ ID 
NO. 12) for a 265 hp product, With hNIS-UNMET-L (sense, 
TAGGATAGATAGATAGTAGGGGTGGAT (SEQ ID NO. 
13), and antisense, CTCCACAACCTCCATAAAAA 
CAAATACA) (SEQ ID NO. 14), for a 275 hp product, 
hNIS-MET-C (sense, AGGTCGTGGAGATCGGGGAAC 
(SEQ ID NO. 15) and antisense, ACGATAAACCTCCGAC 
GACACG) (SEQ ID NO. 16) for a 242 hp product, and 
hNIS-UNMET-C (sense, TTATGGAGGTTGTGGAGAT 
TGGGGAAT (SEQ ID NO. 17), and antisense, CATAA 
CAATAAACCTCCAACAACACA) (SEQ ID NO. 18), for 
a 252 hp product. The ampli?cation conditions Were: Taq 
polymerase activation at 95° C. for 5 min, 40 cycles of: 
denaturation at 94° C. for 20 s, annealing at 60° C. for 30 s 
and polymeriZation at 72° C. for 30 s. MS-PCR products 
Were resolved by agarose gel electrophoresis and visualized 
by ethidium bromide staining and UV transillumination. 
Iodide Uptake Assay 
Cell lines, treated With differentiation agents and control 
cultures, Were Washed With 2 mL of buffer containing: 10 
mM HEPES (pH 8.3), 5.5 mM glucose, 5.4 mM KCl, 1.3 
mM CaCl2, 0.4 mM Na2HPO4, 0.44 mM KH2PO4, and 
either 137 mM NaCl (Buffer A) or 100 mM choline chloride 
(Buffer B). After a 60 min incubation in the same buffer 
supplemented With Na(125 I) (1.0 uCi/ 2 mL) and 1.0 uM NaI, 
cells Were Washed once With Buffer A, lysed With 0.1 M 
NaOH and gamma counted (5). A parallel set of dishes, 
similarly plated and treated, Were used for normaliZation of 
uptake activity, using 3-(4,5-dimethylthiaZol-2-yl)-2,5 
diphenyltetraZolium hromide (MTT) assay (25) as an index 
of cell viability. Gamma counts of cells incubated in Buffer 
B were subtracted from counts of cells incubated in Buffer 
A, under corresponding conditions, to account for non 
speci?c binding of radioiodide. 
Clinical Radioiodine Uptake 
Assessment of radioiodine uptake in clinical tumor 
samples was based upon the results of I-131 whole body 
scans (using 5 mCi I-131 tracer doses), performed 648 
Weeks after excision of the primary tumor during surgical 
thyroidectomy. The presence of radioiodine uptake in meta 
static tumor deposits Was presumed to he indicative of 
positive radioiodine uptake in the primary tumor sample. 
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This is based upon the assumption that tumor redilferentia 
tion, spontaneously restoring loss of iodide uptake, is far less 
common than tumor dedi?‘erentiation. The absence of radio 
iodine uptake in palpahle or radiologically discernihle tumor 
metastases Was presumed to re?ect loss of radioiodine 
uptake in the primary tumor sample. This designation is 
likely correct; hoWever it is possible that metastases may 
have less functionality than their parent tumors. In the 
absence of persistent tumor metastases, the assessment of 
radioiodine uptake Was not possible. Some tumor samples 
were obtained from recurrent tumors Which had been docu 
mented to lack radioiodine uptake on the basis of previous 
whole body scanning. 
Example 2 
Results 
CpG Dinucleotide Distribution in the Context of the hNIS 
Promoter 
The hNIS promoter region, and its contiguous doWn 
stream regions up to the ?rst intron, Were analyZed for the 
presence of CpG islands. The frequency plot (FIG. 1) shoWs 
a region of the promoter, surrounding the transcription start 
site (5) and extending upstream for about 100 base pairs, to 
he rich in CpG dinucleotides (region P). This Was the only 
upstream region in the characterized promoter that Was 
CpG-rich. Sequence comparison revealed that this region 
shared signi?cant homology to the rat NIS promoter region 
(26). This region Was selected for analysis of methylation 
status in clinical tumors and cell lines. Additional CpG-rich 
sequences are present doWnstream from this region, extend 
ing to the ?rst intron. Regions L and C, selected for 
methylation analysis, corresponded to CpG-rich sequences 
in the hNIS leader and coding regions, respectively, Within 
the ?rst exon. 
hNIS mRNA expression and Clinical Iodide Uptake in 
Thyroid Carcinoma 
Primary thyroid tumors Were analyzed by RT-PCR for the 
expression of hNIS mRNA (FIG. 2 and Table 1). Messenger 
RNA for hNIS Was poorly expressed in all of six tall cell 
papillary carcinomas, ranging from undetectable in four 
tumors and moderately positive in tWo tumors (?ve cases 
shoWn in FIG. 2). In contrast, hNIS mRNA expression Was 
clearly detectable in both of the follicular carcinomas, 9 of 
10 typical papillary carcinomas (variahle levels of expres 
sion), and in both of tWo anaplastic thyroid carcinomas. TWo 
of the three Hiirthle cell carcinomas Were negative for hNIS 
mRNA expression. Among the 19 tumor samples Which 
were able to he assessed for clinical radioiodide uptake, 13 
cases exhihited concordance of hNIS mRNA expression 
With whole body scanning (7 With concordant positive 
?ndings and 6 With concordant negative ?ndings). In 6 cases 
(dispersed between all of the tumor histologies except 
follicular carcinoma) there Was no detectable radioiodine 
uptake on whole body scanning despite detectahle hNIS 
mRNA in the tumor sample. Analysis of thyroid transcrip 
tion factor mRNA expression in these discordant cases 
revealed that all expressed PAX-8 and only 2 of the 6 cases 
expressed TTF-l. Since only one of 7 tumor samples, With 
concordant positive radioiodine uptake and hNIS mRNA 
expression, lacked TTF-l mRNA expression, loss of this 
factor may contribute to loss of hNIS function, but is not 
totally explanatory. 
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Methylation Status and hNIS mRNA Expression in Thyroid 
Cancers 
The NIS promoter Was only faintly methylated in normal 
human thyroid tissues and in pooled human White blood 
cells. As described in the previous section, hNIS mRNA Was 
undetectable in four out of six tall cell papillary carcinomas 
and loW in the other tWo. In all of these six cases the hNIS 
promoter (region P) Was strongly methylated (FIG. 3 and 
Table 1). Region L Was methylated in all but one case, 
although displaying loWer signal intensities for the methy 
lated ampli?cation product. A CpG-rich segment of the 
coding region (Region C) displayed heterogeneous methy 
lation among tall cell tumors, Without any particular corre 
lation to hNIS mRNA expression. However, of the ten 
papillary thyroid tumors, there Was no apparent association 
of methylation, in Regions P, L, or C, With loss of hNIS 
mRNA expression. Likewise, although both follicular car 
cinomas expressed hNIS mRNA, they each shoWed different 
methylation patterns betWeen the regions. All of the three 
cases of Hiirthle cell carcinoma had unmethylated hNIS 
promoter regions, and variably methylated L and C regions, 
but only one of them expressed hNIS mRNA. 
Treatment of Thyroid Carcinoma Cell Lines to Restore 
Expression of hNIS mRNA and Effect on Iodide Uptake 
Seven human thyroid neoplastic cell lines, devoid of hNIS 
mRNA expression under basal monolayer conditions, Were 
treated With putative chemical demethylation agents in an 
attempt to restore hNIS expression. These cell lines Were 
derived from three papillary carcinomas (NPA’87, KAT-5, 
and KAT-10), tWo follicular carcinomas (WRO82 and 
MRO87) and tWo benign follicular neoplasms (KAK-l and 
KAK 50) (5). Three different demethylation or redilferen 
tiation agents (viZ., sodium butyrate, phenylacetate and 
5-aZacytidine) Were tested on each of 7 cell lines for their 
ability to induce re-expression of hNIS mRNA. Re-expres 
sion of hNIS mRNA Was achieved in all three of the 
papillary cell lines and one of the benign follicular 
adenomas under at least one treatment condition (Table 2). 
FIG. 4, a and b, demonstrate the hNIS mRNA re-expression 
in cell lines KAK-l and NPA’87, respectively. 
To investigate Whether re-expression of NIS mRNA is 
su?icient to restore hNIS function, i.e., iodide uptake, We 
treated responding cells under the same conditions as used 
to restore mRNA expression and analyZed for 125I uptake 
activity. Of the four responding cell lines tested, there Was 
a greater than tWo-fold increase in uptake in KAK-l cells 
(derived from a benign follicular adenoma) When treated 
With 1.0 uM 5-aZacytidine as compared With untreated cells 
(FIG. 5a). HoWever, no enhancement of uptake Was seen 
using 0.5 uM 5-aZacytidine, even though re-expression of 
hNIS mRNA Was comparable under the tWo different con 
centrations of 5-aZacytidine (FIG. 4a). The iodide uptake 
activity in NPA’87 cells (derived from a papillary carci 
noma) Was slightly increased With 1.0 mM sodium butyrate 
While 1.0 M 5-aZacytidine treatment resulted in over 15-fold 
increased uptake (FIG. 5b). As in the other cell line, the 
differences in iodide uptake Were noted despite similar 
expression of hNIS mRNA (FIG. 4b), suggesting the pos 
sible contribution of some other inducible factor. 
Restoration of Iodide Uptake and Demethylation of hNIS 
Promoter 
The cell lines KAK-l, KAT-5, KAT-10 and NPA’87, in 
Which hNIS expression Was restored, Were groWn under 
basal and re-expression conditions and the DNA Were ana 
lyZed for their methylation status at the same three gene 
regions as studied in the tumors (Table 2). This analysis 
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revealed that the P region Was unmethylated under all 
conditions, basal or otherWise. Methylation of the L and C 
regions, under basal conditions, Was clearly evident in all 
four cell lines. The PCR product speci?c for unmethylated 
DNA in the L and C regions Was undetectable or merely 
faintly present in the same cell lines, suggesting that the cell 
populations Were homogeneously methylated in these 
regions. Treatment With 5-aZacytidine Was associated With 
decreased methylation at the L and C regions in all four cell 
lines, as evidenced by decreased intensity of the methyla 
tion-speci?c PCR products and de novo or increased expres 
sion of the corresponding unmethylated PCR products to 
equal or greater intensity than the methylated product bands. 
The susceptibility of KAT-5 and KAT-10 cells to the dem 
ethylation effects of 5 -aZacytidine in the C region appeared 
less than that of the L region. Although sodium butyrate 
treatment Was associated With re-expression of hNIS mRNA 
in both NPA’87 and KAT-10, With phenylacetate having a 
lesser effect in KAT-5, analysis of methylation patterns of 
the NPA’87 and KAT-10 response to sodium butyrate failed 
to demonstrate effects on altering baseline methylation pat 
terns in all three regions. 
In the three cell lines that failed to express hNIS mRNA, 
despite treatment With 5-aZacytidine, sodium butyrate, or 
phenylacetate (MRO87, WRO82, and KAT-7), baseline 
methylation pattern analysis revealed that region P Was not 
methylated While regions L and C Were homogeneously 
methylated. Treatment With 5-aZacytidine did not affect the 
baseline demethylated status in the P region of these cell 
lines; hoWever the results in the L and C regions Were 
different than seen in the four responding cell lines. Region 
C appeared methylated under basal conditions in the three 
cell lines (analysis of WRO82 failed to reveal either methy 
lated or unmethylated products) and did not become dem 
ethylated in response to 5-aZacytidine, except for minimal 
detection of an unmethylated product for WRO82 cells (a 
methylated product becomes clearly visible). The demethy 
lation response, to 5-aZacytidine in the L region, Was similar 
in both responsive and non-responsive cell lines. The failure 
of 5-aZacytidine to effectively demethylate the C region 
distinguished cell lines Which failed to re-express hNIS 
mRNA from those Which regained such expression. 
Comparison of hNIS Re-expression to Expression Patterns 
of TTF-1 and PAX-8 
To explore the possibility that re-expression of hNIS 
mRNA may be consequent to re-expression of one or more 
transcription factor(s) RT-PCR analysis Was performed for 
thyroid-speci?c transcription factors, TTF-1 and Pax-8 
(Table 2). Pax-8 mRNA Was found to be expressed under all 
conditions tested, in all of the four cell lines Which Were able 
to re-express hNIS mRNA, While TTF-1 mRNA expression 
Was found even under basal conditions in the cell lines 
NPA’87 and KAK-l (data not shoWn). Basal TTF-1 expres 
sion Was undetectable in cell lines KAT-5 and KAT-10, 
although TTF-1 mRNA expression Was induced by 5-aZa 
cytidine treatment. LikeWise, phenylacetate treatment 
induced TTF-1 mRNA expression only in the KAT-5 cell 
line, hoWever sodium butyrate did not have such an effect in 
either of the cell lines. 
Example 3 
Inhibition of Polyamine Synthesis Restores Sodium/Iodide 
Symporter Gene Expression and Activity in Dedilferentiated 
Thyroid Carcinoma Cell Lines 
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hNIS transcriptional failure in thyroid carcinoma could be 
consequent to methylation of DNA in critical regulatory 
regions and could be reversed by inhibition of DNA-meth 
yltransferase. Restoration of hNIS gene expression and 
activity from direct DNA-methyltransferase inhibition by 
5-aZacytidine has been shoWn. Reports suggest that decar 
boxylated S-adenosylmethionine (dcSAM) is an endog 
enous inhibitor of DNA methylation, competing against the 
methyl-donor, S-adenosylmethionine. Since dcSAM is con 
sumed by synthesis of polyamines (putrescine, spermidine, 
spermine) and its synthetic enzyme (adenosylmethionine 
decarboxylase) is stimulated by polyamine depletion, block 
ade of polyamine synthesis precipitously increases dcSAM 
levels. This should block DNA-methyltransferase activity 
and restore lost hNIS expression in dedilferentiated thyroid 
carcinomas. To assess this, human thyroid cell lines 
(NPA’87, papillary carcinoma, & KAK-l, follicular 
adenoma) Without basal expression of hNIS or thyroglobulin 
(TG) mRNAs, Were groWn as monolayers in phenol red-free 
RPMI 1640 With 10% fetal bovine serum. Starting 24 hrs 
after plating and for 6 days (replacing media & agent every 
other day), cells Were treated With di?uoromethylomithine 
(DFMO, at 1 or 3 mM; an inhibitor of ornithine decarboxy 
lase, blocking putrescine synthesis) or S-adenosyl-1,8-di 
amino-3-thio-octane (AdoDATO, at 10 or 30 uM; an ami 
nopropyltransferase inhibitor blocking spermidine synthase 
and spermine synthase). Cells Were harvested for RNA, 
subjected to reverse transcriptase With random hexamer 
priming for cDNA, and then polymerase chain reactions 
With primers to amplify: hNIS, TG, thyroid peroxidase 
(TPO), and [3-actin. Parallel cultures Were assessed for 
Na[l25l] uptake (RAIU) in serum-free buffer, subtracting 
1251 counts in buffer With choline (100 mM) to correct for 
non-speci?c counts and results normaliZed for cell density in 
each condition using thiaZolyl blue (MTT) assays. In both 
cell lines, DFMO and AdoDATO restored hNIS and TG 
mRNA expression, With higher doses having greater effect. 
Both cell lines had minimal basal TPO expression With each 
reagent enhancing expression at every dosage. DFMO at 3 
mM caused greatest increases in RAlU (>6-fold) in NPA’87 
cells and 30 uM AdoDATO had the greatest response 
(~5-fold) in KAK-l cells. This supports DNA-methylation 
as a reversible cause of loss of iodide transport in dedilfer 
entiated thyroid carcinoma and endorses polyamine inhibi 
tion as a therapeutic method to restore responsiveness to 
radioiodine therapy. 
Whereas particular embodiments of this invention have 
been described above for purposes of illustration, it Will be 
evident to those persons skilled in the art that numerous 
variations of the details of the present invention may be 
made Without departing from the invention as de?ned in the 
appended claims. 
All of the references cited herein are incorporated by 
reference in their entirety. 
TABLE 1 
Thyroid tissue analysis 
Methylation Status Clinical 
Tumor Sample by Region hNIS mRNA Radioiodine 
Histology Number P L C Expression Uptake 
Typical 1 — + + ++ + 
papillary 2 — — — N.A. 
Carcinoma — 
20 
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TABLE 1-continued 
Thyroid tissue analysis 
Methylation Status Clinical 
Tumor Sample by Region hNIS mRNA Radioiodine 
Histology Number P L C Expression Uptake 
3 + faint + + 
4 — — + + 
5 — + + ++ NA. 
6 ++ — + ++ + 
7 ++ + ++ + + 
8 — + + + 
9 + ++ ++ + — 
10 + — + — 
Tall-cell 11 ++ faint ++ — — 
variant 12 ++ + ++ + — 
Papillary 13 + + faint — — 
carcinoma 14 ++ + — — 
15 ++ + faint — — 
16 + — + — 
Follicular 17 + faint ++ + 
Carcinoma — 
18 — faint ++ ++ N.A. 
Hiirthle cell 19 — — + ++ — 
Carcinoma 20 — + — — 
21 — — ++ — — 
Anaplastic 22 ++ — + + N.A. 
Carcinoma 23 — — ++ — 
faint 
Normal 24 faint — ++ +* 
Thyroid — 
Tissue 25 faint — ++ +* 
26 — — + ++ +* 
27 faint — + ++ +* 
28 faint — ++ +* 
Methylation: ++, distinctly positive; +, moderately positive; faint, slightly 
positive; —, negative. 
mRNA expression: ++, comparable to normal thyroid; +, moderate level; 
—, negative. 
Clinical radioiodine uptake: +, positive tumor uptake; +*, assumed (patient 
euthyroid); —, no tumor uptake; N.A., results not available. 
US 7,029,879 B1 
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TABLE 2 
16 
Hurnan thyroid cell line analysis 
Methylation Status 
Culture hNIS Speci?c 1251 by Region TTF-l Pax-8 
Cell Line Additive mRNA Uptake P L C mRNA mRNA 
NPA'87 None — — — + + + + 
AzaC-low — — nd nd nd nd nd 
AzaC-high + + — — — + + 
NaB-loW — — nd nd nd nd nd 
NaB-high + — — + + + + 
PhAc-loW — — nd nd nd nd nd 
PhAc-high — nd nd nd nd nd 
KAK-l None — — — + + + + 
AzaC-loW + — — — — + + 
AzaC-high + + — — — + + 
NaB-loW — — nd nd nd nd nd 
NaB-high — — nd nd nd nd nd 
PhAc-loW — — nd nd nd nd nd 
PhAc-high — — nd nd nd nd nd 
KAT-5 None — — — + + — + 
AzaC-low — — nd nd nd nd nd 
AzaC-high + — — — — + + 
NaB-loW — — nd nd nd nd nd 
NaB-high — — nd nd nd nd nd 
PhAc-loW — — nd nd nd nd nd 
PhAc-high + — — + + + + 
KAT-10 None — — — + + — + 
AzaC-loW + — — — — + + 
AzaC-high Lethal additive concentration for this cell line 
NaB-loW — — nd nd nd nd nd 
NaB-high + — — + + — + 
PhAc-loW — — nd nd nd nd nd 
PhAc-high — — nd nd nd nd nd 
Culture Additives: AzaC, 5-azacytidine (loW, 0.5 uM; high, 1.0 uM); NaB, sodiuIn 
butyrate (loW, 0.5 mM; high, 1.0 mM); and PhAc, phenylacetate (loW, 5.0 mM; high, 10 
mM). 
Speci?c 1251 uptake (monolayer cultures): +, positive; and —, negative. 
Methylation: +, positive, —, negative. 
mRNA expression (hNIS, TTF-l, Pax-8): +, positive; —, negative; and nd, not done. 
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SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOS: l6 
<2 10> SEQ ID NO 1 
<211> LENGTH: 32 
<2 12> TYPE: DNA 
<2 13> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: primer 
<400> SEQUENCE: l 
gtcgacatgg atctgcaaac ctcgttgctg tg 32 
<2 10> SEQ ID NO 2 
<211> LENGTH: 32 
<2 12> TYPE: DNA 
<2 13> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: primer 
<400> SEQUENCE: 2 
actagttcag gtgcctttgc tttctgtcct ct 32 
<2 10> SEQ ID NO 3 
<211> LENGTH: 353 
<2 12> TYPE: PRT 
<2 13> ORGANISM: Rat 
<400> SEQUENCE: 3 
Met Asp Leu Gln Thr Ser Leu Leu Ser Thr Gly Pro Asn Ala Ser Asn 
1 5 10 15 
Ile Ser Asp Gly Gln Asp Asn Leu Thr Leu Pro Gly Ser Pro Pro Arg 
20 25 30 
Thr Gly Ser Val Ser Tyr Ile Asn Ile Ile Met Pro Ser Val Phe Gly 
35 40 45 
Thr Ile Cys Leu Leu Gly Ile Val Gly Asn Ser Thr Val Ile Phe Ala 
50 55 60 
Val Val Lys Lys Ser Lys Leu His Trp Cys Ser Asn Val Pro Asp Ile 
Phe Ile Ile Asn Leu Ser Val Val Asp Leu Leu Phe Leu Leu Gly Met 
85 90 95 
Pro Phe Met Ile His Gln Leu Met Gly Asn Gly Val Trp His Phe Gly 
100 105 110 
Glu Thr Met Cys Thr Leu Ile Thr Ala Met Asp Ala Asn Ser Gln Phe 
115 120 125 
Thr Ser Thr Tyr Ile Leu Thr Ala Met Thr Ile Asp Arg Tyr Leu Ala 
130 135 140 
Thr Val His Pro Ile Ser Ser Thr Lys Phe Arg Lys Pro Ser Met Ala 
145 150 155 160 
Thr Leu Val Ile Cys Leu Leu Trp Ala Leu Ser Phe Ile Ser Ile Thr 
165 170 175 






